List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 16
Figure 4. Asia Pacific Genital Herpes Treatment Market, 2022-2032, $ mn 19
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Genital Herpes Treatment Market 25
Figure 7. Forecast of Middle-class Population by Region, 2015-2030, million 28
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Genital Herpes Treatment Market 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Genital Herpes Treatment Market 36
Figure 11. Breakdown of Asia Pacific Genital Herpes Treatment Market by Virus Type, 2022-2032, % of Revenue 41
Figure 12. Asia Pacific Addressable Market Cap in 2023-2032 by Virus Type, Value ($ mn) and Share (%) 41
Figure 13. Asia Pacific Genital Herpes Treatment Market by Virus Type: HSV-1, 2022-2032, $ mn 42
Figure 14. Asia Pacific Genital Herpes Treatment Market by Virus Type: HSV-2, 2022-2032, $ mn 43
Figure 15. Breakdown of Asia Pacific Genital Herpes Treatment Market by Drug Type, 2022-2032, % of Sales Revenue 45
Figure 16. Asia Pacific Addressable Market Cap in 2023-2032 by Drug Type, Value ($ mn) and Share (%) 45
Figure 17. Asia Pacific Genital Herpes Treatment Market by Drug Type: Acyclovir, 2022-2032, $ mn 46
Figure 18. Asia Pacific Genital Herpes Treatment Market by Drug Type: Valacyclovir, 2022-2032, $ mn 47
Figure 19. Asia Pacific Genital Herpes Treatment Market by Drug Type: Famciclovir, 2022-2032, $ mn 48
Figure 20. Asia Pacific Genital Herpes Treatment Market by Drug Type: Other Drugs, 2022-2032, $ mn 49
Figure 21. Breakdown of Asia Pacific Genital Herpes Treatment Market by Route of Administration, 2022-2032, % of Sales Revenue 52
Figure 22. Asia Pacific Addressable Market Cap in 2023-2032 by Route of Administration, Value ($ mn) and Share (%) 52
Figure 23. Asia Pacific Genital Herpes Treatment Market by Route of Administration: Oral, 2022-2032, $ mn 53
Figure 24. Asia Pacific Genital Herpes Treatment Market by Route of Administration: Topical, 2022-2032, $ mn 54
Figure 25. Asia Pacific Genital Herpes Treatment Market by Route of Administration: Injection, 2022-2032, $ mn 55
Figure 26. Breakdown of Asia Pacific Genital Herpes Treatment Market by Patient Gender, 2022-2032, % of Revenue 57
Figure 27. Asia Pacific Addressable Market Cap in 2023-2032 by Patient Gender, Value ($ mn) and Share (%) 57
Figure 28. Asia Pacific Genital Herpes Treatment Market by Patient Gender: Female, 2022-2032, $ mn 58
Figure 29. Asia Pacific Genital Herpes Treatment Market by Patient Gender: Male, 2022-2032, $ mn 59
Figure 30. Breakdown of Asia Pacific Genital Herpes Treatment Market by Distribution Channel, 2022-2032, % of Revenue 61
Figure 31. Asia Pacific Addressable Market Cap in 2023-2032 by Distribution Channel, Value ($ mn) and Share (%) 61
Figure 32. Asia Pacific Genital Herpes Treatment Market by Distribution Channel: Retail Pharmacies, 2022-2032, $ mn 62
Figure 33. Asia Pacific Genital Herpes Treatment Market by Distribution Channel: Hospital Pharmacies, 2022-2032, $ mn 63
Figure 34. Asia Pacific Genital Herpes Treatment Market by Distribution Channel: Online Pharmacies, 2022-2032, $ mn 64
Figure 35. Asia Pacific Genital Herpes Treatment Market by Distribution Channel: Drug Stores, 2022-2032, $ mn 65
Figure 36. Breakdown of APAC Genital Herpes Treatment Market by Country, 2022 and 2032, % of Revenue 67
Figure 37. Contribution to APAC 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 68
Figure 38. Genital Herpes Treatment Market in Japan, 2022-2032, $ mn 70
Figure 39. Genital Herpes Treatment Market in China, 2022-2032, $ mn 72
Figure 40. Genital Herpes Treatment Market in Australia, 2022-2032, $ mn 74
Figure 41. Genital Herpes Treatment Market in India, 2022-2032, $ mn 76
Figure 42. Genital Herpes Treatment Market in South Korea, 2022-2032, $ mn 78
Figure 43. Genital Herpes Treatment Market in Rest of APAC, 2022-2032, $ mn 80
Figure 44. Growth Stage of Asia Pacific Genital Herpes Treatment Industry over the Forecast Period 82
Asia Pacific genital herpes treatment market will grow by 6.3% annually with a total addressable market cap of $10,932.1 million over 2023-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiviral medications, and the government supports. Highlighted with 32 tables and 44 figures, this 110-page report “Asia Pacific Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gender (Female, Male), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores), and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific genital herpes treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific genital herpes treatment market in every aspect of the classification from perspectives Virus, Drug Type, Route of Administration, Patient Gender, Distribution Channel, and Country. Based on Virus Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • HSV-1 • HSV-2 Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Acyclovir • Valacyclovir • Famciclovir • Other Drugs By Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Oral • Topical • Injection By Patient Gender, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Female • Male By Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies • Drug Stores Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Virus Type, Drug Type and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott ADLEY FORMULATIONS Aurobindo Pharma Ltd. Avet Pharmaceuticals Inc. Bausch Health Companies Centurion Remedies Cipla Ltd. Eli Lilly & Company Finecure Pharmaceuticals GlaxoSmithKline Plc Glenmark Pharmaceuticals Macleods Pharmaceuticals Medico Remedies Merck & Co., Inc. Novartis AG Pfizer Reddy's Laboratories Sanofi SA Teva Pharmaceutical Industries Ltd. Torrent Pharma Viatris Inc. Zeelab Pharmacy Zydus Pharmaceuticals, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More